TRough versus AUC Monitoring of cyclosporine: A randomized comparison of adverse drug reactions in adult allogeneic stem cell recipients (TRAM study)

To investigate the incidence and severity of adverse drug reactions of cyclosporine using AUC‐targeted therapeutic drug monitoring (TDM) compared to trough level (Ctrough)‐targeted TDM in adult allogeneic stem cell recipients.

[1]  Y. Bertrand,et al.  Goal-oriented monitoring of cyclosporine is effective for graft-versus-host disease prevention after Hematopoietic Stem Cell Transplantation in Sickle Cell Disease and Thalassemia major. , 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[2]  G. Huls,et al.  Cyclosporine A trough concentrations are associated with acute GvHD after non-myeloablative allogeneic hematopoietic cell transplantation , 2019, PloS one.

[3]  J. Janssen,et al.  Clinical Validation of Dried Blood Spot Sampling in Therapeutic Drug Monitoring of Ciclosporin A in Allogeneic Stem Cell Transplant Recipients: Direct Comparison Between Capillary and Venous Sampling , 2013, Therapeutic drug monitoring.

[4]  J. Janssen,et al.  Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy. , 2012, British journal of clinical pharmacology.

[5]  L. Stolk,et al.  Dried Blood Spot Methods in Therapeutic Drug Monitoring: Methods, Assays, and Pitfalls , 2009, Therapeutic drug monitoring.

[6]  H. Nakasone,et al.  Decreased incidence of acute graft‐versus‐host disease by continuous infusion of cyclosporine with a higher target blood level , 2008, American journal of hematology.

[7]  R. Storb,et al.  Extending Postgrafting Cyclosporine Decreases the Risk of Severe Graft-versus-Host Disease after Nonmyeloablative Hematopoietic Cell Transplantation , 2006, Transplantation.

[8]  D. Abendroth.  Experience with therapeutic drug monitoring of cyclosporine. , 2004, Transplantation proceedings.

[9]  W. Weimar,et al.  Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR‐1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus , 2003, Clinical pharmacology and therapeutics.

[10]  M. Zembala,et al.  Influence of long term cyclosporine therapy on insulin and its precursors secretion in patients after heart transplantation. , 2003, Annals of Transplantation.

[11]  R. Storb,et al.  Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissio , 2003, Blood.

[12]  Atholl Johnston,et al.  Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. , 2002, Clinical therapeutics.

[13]  H. Vapaatalo,et al.  Cyclosporine A-induced Hypertension and Nephrotoxicity in Spontaneously Hypertensive Rats on High-sodium Diet , 2022 .

[14]  N. Perico,et al.  Pharmacokinetic study of the new cyclosporine-A formulation (Neoral) in adult allogeneic bone marrow transplant recipients. , 2001, Haematologica.

[15]  G. Levy,et al.  Impact of Absorption Profiling on Efficacy and Safety of Cyclosporin Therapy in Transplant Recipients , 2000, Clinical pharmacokinetics.

[16]  B. Kahan.  Optimization of cyclosporine therapy. , 1993, Transplantation proceedings.

[17]  B. Kahan,et al.  Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation , 1993, Clinical pharmacology and therapeutics.

[18]  C. P. Wang,et al.  The kinetics of cyclosporine and its metabolites in bone marrow transplant patients. , 1991, British journal of clinical pharmacology.